St. Jude Medical

Belkins
St. Jude Medical is now Abbott. We are a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. We do this by developing cost-effective medical technologies that save and improve lives. St. Jude Medical provides safe and effective technologies that are of the highest quality-and that quality is something we take very seriously because we know patients around the world rely on our technologies. Our approximately 18,000 employees are passionate in their commitment to this priority.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ST. JUDE MEDICAL HEARTMATE 3 LVAS DEMONSTRATED IMPROVED CLINICAL OUTCOMES FOR PATIENTS SUFFERING FROM ADVANCED HEART FAILURE

St. Jude Medical | November 16, 2016

news image

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial session at the American Heart Association (AHA) Scientific Sessions in New Orleans. The MOMENTUM 3 study compared the HeartMate 3™ Left Ventricular Assist System (LVAS) to the HeartMate II™ LVAS in treating advanced stage heart failure and is the largest LVAD trial in the world to evaluate both short-term and long-...

Read More

ILUMIEN III CLINICAL TRIAL RESULTS FROM ST. JUDE MEDICAL DEMONSTRATE IMPORTANT FINDINGS WITH ADVANCED INTRAVASCULAR IMAGING TECHNOLOGY

St. Jude Medical | October 30, 2016

news image

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the ILUMIEN III trial met its primary endpoint demonstrating percutaneous coronary intervention (PCI) guided by optical coherence tomography (OCT) to be superior to angiography in stent expansion and procedural success and non-inferior to intravascular ultrasound (IVUS) guided-PCI in post-procedure minimal stent area (MSA)....

Read More

ST. JUDE MEDICAL ANNOUNCES FDA APPROVAL AND U.S. LAUNCH OF THE FIRST AND ONLY MEDICAL DEVICE

St. Jude Medical | October 28, 2016

news image

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the U.S. Food and Drug Administration (FDA) approval and launch of the AMPLATZER™ PFO Occluder to help reduce the risk of recurrent ischemic strokes in patients diagnosed with a patent foramen ovale (PFO) – a small opening between the upper chambers of the heart....

Read More

ST. JUDE MEDICAL ANNOUNCES DATA TO BE PRESENTED AS LATE-BREAKING CLINICAL TRIALS

St. Jude Medical | October 24, 2016

news image

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced today that it will have new data featured during late-breaking clinical trial presentations at the upcoming 2016 Transcatheter Cardiovascular Therapeutics educational meeting in Washington, D.C., October 29 – November 2....

Read More
news image

ST. JUDE MEDICAL HEARTMATE 3 LVAS DEMONSTRATED IMPROVED CLINICAL OUTCOMES FOR PATIENTS SUFFERING FROM ADVANCED HEART FAILURE

St. Jude Medical | November 16, 2016

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial session at the American Heart Association (AHA) Scientific Sessions in New Orleans. The MOMENTUM 3 study compared the HeartMate 3™ Left Ventricular Assist System (LVAS) to the HeartMate II™ LVAS in treating advanced stage heart failure and is the largest LVAD trial in the world to evaluate both short-term and long-...

Read More
news image

ILUMIEN III CLINICAL TRIAL RESULTS FROM ST. JUDE MEDICAL DEMONSTRATE IMPORTANT FINDINGS WITH ADVANCED INTRAVASCULAR IMAGING TECHNOLOGY

St. Jude Medical | October 30, 2016

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the ILUMIEN III trial met its primary endpoint demonstrating percutaneous coronary intervention (PCI) guided by optical coherence tomography (OCT) to be superior to angiography in stent expansion and procedural success and non-inferior to intravascular ultrasound (IVUS) guided-PCI in post-procedure minimal stent area (MSA)....

Read More
news image

ST. JUDE MEDICAL ANNOUNCES FDA APPROVAL AND U.S. LAUNCH OF THE FIRST AND ONLY MEDICAL DEVICE

St. Jude Medical | October 28, 2016

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the U.S. Food and Drug Administration (FDA) approval and launch of the AMPLATZER™ PFO Occluder to help reduce the risk of recurrent ischemic strokes in patients diagnosed with a patent foramen ovale (PFO) – a small opening between the upper chambers of the heart....

Read More
news image

ST. JUDE MEDICAL ANNOUNCES DATA TO BE PRESENTED AS LATE-BREAKING CLINICAL TRIALS

St. Jude Medical | October 24, 2016

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced today that it will have new data featured during late-breaking clinical trial presentations at the upcoming 2016 Transcatheter Cardiovascular Therapeutics educational meeting in Washington, D.C., October 29 – November 2....

Read More